# BiomX Inc. > Clarifo company profile — qualitative business description generated from > the company's filings. Financial statements, charts and ratios are > available on Clarifo (https://www.clarifo.com/en/companies/BiomX Inc.). ## Overview BiomX Inc. is a U.S.-listed biotechnology company focused on developing bacteriophage-based therapies for serious bacterial infections. Its reported pipeline has centered on BX011 for diabetic foot infections and earlier programs including BX004, which was discontinued in 2025. The company’s Israeli operating subsidiary, BiomX Ltd., entered insolvency proceedings in December 2025, materially reducing the group’s operating capacity and leaving BiomX Inc. with limited ongoing operations. As a result, the company is actively evaluating strategic alternatives and other business opportunities while seeking additional financing and control of its remaining assets and expertise. ## Products & services • BX011 bacteriophage therapy for diabetic foot infections • BX004 program for cystic fibrosis-related bacterial infection • Phage discovery and development platform • Preclinical and clinical development services for internal pipeline • Technology licensing and collaboration opportunities - **Clinical-stage phage therapeutics** (80%) — Drug candidates designed to treat bacterial infections using bacteriophages, including BX011 and the discontinued BX004 program. - **Platform discovery and R&D** (15%) — Internal phage discovery, engineering, and translational research used to generate new therapeutic candidates. - **Licensing and collaboration** (5%) — Potential technology licenses, research collaborations, and related milestone or grant-based income. - BX011 bacteriophage therapy for diabetic foot infections - BX004 program for cystic fibrosis-related bacterial infection - Phage discovery and development platform - Preclinical and clinical development services for internal pipeline - Technology licensing and collaboration opportunities ## Customers BiomX does not currently sell approved products, so its direct customer base is not commercial end-users but rather future healthcare buyers and research partners. If successful, its therapies would be purchased by hospitals, wound-care specialists, infectious disease physicians, and healthcare systems treating difficult bacterial infections such as diabetic foot infections. The company also relies on collaborators, grant providers, and potential licensing partners to fund development and validate its platform. In the near term, its economic counterparties are primarily investors, government grant agencies, and strategic partners rather than patients or pharmacies. - **Healthcare providers** (primary) — Hospitals, wound-care centers, and physicians would buy approved phage therapies if the company reaches commercialization, because these infections are clinically difficult and often resistant to standard antibiotics. - **Strategic partners** (secondary) — Biopharma collaborators may license BiomX technology or co-develop candidates to share development risk and access the phage platform. - **Government grant agencies** (secondary) — Public innovation bodies fund preclinical and clinical work through grants, helping offset R&D spend and extend runway. - **Capital providers** (primary) — Equity and preferred-stock investors finance operations because the company has no product revenue and depends on external capital. - Hospitals and wound-care providers that would use BX011 for diabetic foot infections - Infectious disease clinicians seeking alternatives for hard-to-treat bacterial infections - Potential pharmaceutical or biotech partners for licensing and co-development - Government grant agencies such as the Israeli Innovation Authority and MTEC - Investors providing equity or convertible financing to fund R&D ## Geography BiomX is headquartered in the United States, but its historical operating base has been in Israel through BiomX Ltd., which housed a significant portion of the workforce and core R&D activity. The 2025 insolvency of the Israeli subsidiary materially disrupted operations and reduced the company’s ability to advance programs from that location. The company also references collaboration and grant relationships with Israeli institutions, including the Israeli Innovation Authority, which have supported development activity. Geography therefore matters mainly through R&D execution, labor availability, and exposure to Israeli operating and geopolitical conditions rather than through commercial sales markets. - **United States** (50%) — Estimated as corporate headquarters and listing base; no country revenue disclosure. - **Israel** (50%) — Estimated as historical core operating and R&D base through BiomX Ltd.; no country revenue disclosure. - United States headquarters and public listing base - Israel as the historical core R&D and operating center - Israeli subsidiary insolvency materially reduced operating capacity - Grant and collaboration exposure to Israeli institutions - No disclosed commercial revenue geography because no product sales ## Strategy BiomX’s near-term strategy is centered on preserving liquidity, pursuing strategic alternatives, and determining whether any remaining assets, expertise, or programs can be monetized or repositioned. Before the insolvency of BiomX Ltd., the company’s operating strategy focused on advancing BX011 and BX004 through preclinical and clinical development, with the longer-term goal of securing regulatory approval and commercialization. Management has also indicated a willingness to seek technology licensing, collaborations, or additional product candidates if those paths can create value with limited resources. Given the change in control risk from the 2025 preferred-stock financing, the company’s strategic direction may shift materially depending on shareholder approval and the outcome of restructuring efforts. - **Strategic alternatives and restructuring** (short-term) — The insolvency of BiomX Ltd. and limited remaining operations make asset monetization, restructuring, or a business pivot the central near-term priority. - **Liquidity preservation and financing** (short-term) — The company has no product revenue and depends on external capital to continue any R&D or corporate activity. - **Advance BX011 and other phage assets if feasible** (medium-term) — Clinical progress is necessary to create any future commercial or partnering value from the platform. - Preserve cash and extend runway while operations are limited - Pursue strategic alternatives after the Israeli subsidiary insolvency - Advance or monetize remaining phage assets if resources allow - Seek licensing, collaboration, or acquisition opportunities - Depend on external financing to fund any continued development ## Risks BiomX faces severe company-specific execution risk because its Israeli operating subsidiary entered insolvency proceedings, materially impairing the organization’s ability to continue development as planned. The company also depends on external financing, and failure to raise capital on acceptable terms could force further downsizing, asset sales, or cessation of operations. As a clinical-stage biotech, it faces high scientific and regulatory risk: product candidates may fail in trials, encounter safety issues, or never obtain approval or market acceptance. Broader industry risks include intense competition from better-capitalized phage and anti-infective developers, manufacturing and raw-material supply constraints, and volatility in biotech equity markets. Geopolitical and regional instability in Israel adds an additional operational and personnel risk given the company’s historical R&D footprint there. - **BiomX Ltd. insolvency and operational disruption** [critical] — The core operating subsidiary entered insolvency proceedings, reducing workforce, R&D continuity, and the company’s ability to advance programs. - **Financing and going-concern pressure** [critical] — With no product sales and limited liquidity, the company may need additional capital or may be unable to continue operations. - **Clinical and regulatory failure** [high] — Phage candidates may fail due to efficacy, safety, or regulatory hurdles, which is common in biotech development. - **Competitive displacement** [medium] — Other phage and anti-infective developers may reach the market first or with superior data, reducing BiomX’s relevance. - **Geopolitical and regional instability in Israel** [medium] — Historical operations and personnel were concentrated in Israel, creating exposure to local conflict and disruption. - Israeli subsidiary insolvency has materially reduced operating capacity - No product revenue means continued dependence on external capital - Clinical failure or safety issues could eliminate pipeline value - Competition from better-funded phage and anti-infective developers - Manufacturing and specialty raw-material supply constraints - Geopolitical exposure tied to Israel-based operations and personnel - Potential dilution from preferred stock, warrants, and future financings ## Accounting BiomX’s financial statements are dominated by judgment-heavy accounting because the company is a pre-revenue biotech with significant R&D spend and limited operating history. Revenue recognition is not currently a major driver because the company has not generated product sales, but any future collaboration or licensing income would require careful assessment of performance obligations and timing. The company records substantial estimates for accrued research and development expenses, which can materially affect quarterly operating loss because CRO, manufacturing, and consultant costs are often incurred before invoices are received. Impairment accounting is especially important: the company recognized charges for goodwill, IPR&D, and other long-lived assets, including write-downs tied to the discontinuation of programs and the insolvency of BiomX Ltd. The company also uses foreign exchange hedges for NIS-denominated payroll and operating costs, so derivative accounting and currency movements can affect reported results. - **Accrued research and development expenses** — Quarterly operating loss and comparability - **IPR&D and goodwill impairment** — Large swings in operating results and asset values - **Foreign exchange hedging** — Earnings volatility and cash flow protection - **Warrant fair value changes** — Non-operating volatility in net loss - Accrued R&D estimates affect quarterly operating expense timing - No product revenue today, but future collaboration/licensing revenue would be judgmental - Goodwill and IPR&D impairment can create large non-cash charges - Long-lived asset impairment reflects program discontinuation and insolvency - Foreign exchange contracts hedge NIS expenses and affect other income/expense - Stock-based compensation and warrant fair value changes can add volatility - Going-concern and liquidity disclosures are important given limited runway --- *Last updated: 2026-08-11T04:46:23.825461+00:00*